Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.
Michael T DurheimElisabeth BendstrupLisa CarlsonEva M SutinenCharlotte HyldgaardDimitrios KalafatisMarjukka MyllärniemiC Magnus SköldTone SjåheimPublished in: Respirology (Carlton, Vic.) (2021)
In a broadly representative IPF population, patients with advanced IPF at the initiation of antifibrotic therapy did not have greater lung function decline over time compared with those with mild-moderate IPF, but had substantially higher mortality. Prospective studies are needed to determine the effect of antifibrotic therapy in patients with advanced IPF.
Keyphrases
- idiopathic pulmonary fibrosis
- lung function
- interstitial lung disease
- air pollution
- cystic fibrosis
- chronic obstructive pulmonary disease
- cross sectional
- pulmonary fibrosis
- high intensity
- type diabetes
- cardiovascular disease
- risk factors
- study protocol
- insulin resistance
- randomized controlled trial
- coronary artery disease
- metabolic syndrome
- weight loss
- skeletal muscle
- systemic sclerosis
- case control